Cargando…

Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma

Combined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international guidelines for optimal management. For localized tumors, radical resection represents the preferred treatment option, whereas for advanced tumors, s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azizi, Alexander A., Hadjinicolaou, Andreas V., Goncalves, Carla, Duckworth, Adam, Basu, Bristi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545907/ https://www.ncbi.nlm.nih.gov/pubmed/33102226 http://dx.doi.org/10.3389/fonc.2020.570958

Ejemplares similares

Development and Validation of a Nomogram for Differentiating Combined Hepatocellular Cholangiocarcinoma From Intrahepatic Cholangiocarcinoma
por: Wang, Tao, et al.
Publicado: (2020)

Current update on combined hepatocellular-cholangiocarcinoma
por: Maximin, Suresh, et al.
Publicado: (2014)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Preoperative Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Nomogram Based on Ultrasonographic Features and Clinical Indicators
por: Chen, Yanling, et al.
Publicado: (2022)

Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update
por: Roßner, Florian, et al.
Publicado: (2023)

Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach
por: Choi, Joon Hyuk, et al.
Publicado: (2022)

Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma
por: Rhee, Hyungjin, et al.
Publicado: (2021)

Tumor burden score dictates prognosis of patients with combined hepatocellular cholangiocarcinoma undergoing hepatectomy
por: Deng, Gang, et al.
Publicado: (2023)

CEUS and CT/MRI LI-RADS in Association With Serum Biomarkers for Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma
por: Zhou, Yan, et al.
Publicado: (2022)

Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions
por: Stavraka, Chara, et al.
Publicado: (2018)

Prediction of Survival and Analysis of Prognostic Factors for Patients With Combined Hepatocellular Carcinoma and Cholangiocarcinoma: A Population-Based Study
por: Wang, Jitao, et al.
Publicado: (2021)

Anatomical liver resection improves surgical outcomes for combined hepatocellular-cholangiocarcinoma: A propensity score matched study
por: Wang, Wen-qiang, et al.
Publicado: (2022)

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma
por: Renzulli, Matteo, et al.
Publicado: (2021)

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma
por: Zhao, Li-ming, et al.
Publicado: (2023)

Treatment of Combined Hepatocellular and Cholangiocarcinoma
por: Leoni, Simona, et al.
Publicado: (2020)

An Efficient Nomogram for Discriminating Intrahepatic Cholangiocarcinoma From Hepatocellular Carcinoma: A Retrospective Study
por: Si, Yuan-Quan, et al.
Publicado: (2022)

MRI Features of Hepatic Sarcomatoid Carcinoma Different From Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
por: Zhang, Hongbin, et al.
Publicado: (2021)

Advances in prognostic and therapeutic targets for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The hippo signaling pathway
por: Mranda, Geofrey Mahiki, et al.
Publicado: (2022)

Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
por: Auer, Timo Alexander, et al.
Publicado: (2023)

Adjuvant therapy for cholangiocarcinoma after surgery and prognosis factors for cholangiocarcinoma: A single-center retrospective cohort study
por: Sun, Zhongquan, et al.
Publicado: (2023)

Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma
por: Murugesan, Karthikeyan, et al.
Publicado: (2021)

A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China
por: Zhu, Sihui, et al.
Publicado: (2021)

Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
por: Prasopporn, Sunisa, et al.
Publicado: (2022)

Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma
por: Najran, Pavan, et al.
Publicado: (2017)

The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review
por: Cremen, Sinead, et al.
Publicado: (2022)

Outcome of Combined Hepatocellular and Cholangiocarcinoma of the Liver
por: Wang, Jue, et al.
Publicado: (2010)

Exophytic combined hepatocellular carcinoma and cholangiocarcinoma
por: Noh, Sang Jae, et al.
Publicado: (2012)

Combined hepatocellular-cholangiocarcinoma in a cow
por: HONDA, Hidetsugu, et al.
Publicado: (2019)

Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
por: Prasopporn, Sunisa, et al.
Publicado: (2023)

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
por: Xie, Shuqi, et al.
Publicado: (2023)

Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular‐cholangiocarcinoma after resection
por: Song, Peipei, et al.
Publicado: (2019)

Progress in Radiotherapy for Cholangiocarcinoma
por: Wang, Ningyu, et al.
Publicado: (2022)

Interventional Treatment for Cholangiocarcinoma
por: Li, Hang, et al.
Publicado: (2021)

Alternative Splicing-Based Differences Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Genes, Immune Microenvironment, and Survival Prognosis
por: Luo, Dingan, et al.
Publicado: (2021)

RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
por: Sartorius, Kurt, et al.
Publicado: (2022)

Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy
por: Ding, Yuan, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
por: Ouyang, Tao, et al.
Publicado: (2022)

Updates in Cholangiocarcinoma
por: O’Hagan, Kristen
Publicado: (2022)

Lynch syndrome: from detection to treatment
por: Williams, Madeleine H., et al.
Publicado: (2023)

MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma
por: Sammon, Jennifer, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o8lo0ujm2ueh099cn5rii9v0ae